Precigen just posted its first profitable quarter as a commercial company, and the entire equity story now sits on whether PAPZIMEOS, the first approved therapy for adult recurrent respiratory papillomatosis, is a durable franchise or a one-course harvest of a prevalent patient pool. The product is a four-injection subcutaneous immunotherapy that targets the human papillomavirus types that drive the disease. Management framed the second quarter as the launch accelerating into profitability. The market is capitalizing that print as if the run-rate is already the new normal.
Product sales of PAPZIMEOS more than doubled sequentially to $53 million, enough to swing the company to $20 million of net income. That is the strongest commercial evidence the launch has produced. Beneath the income statement, trade receivables climbed to $72 million on payment terms that stretch well past a quarter. Cash plus investments fell to $39 million. That cash sits against $94 million of Pharmakon term debt. The profit is real on an accrual basis. The cash conversion is not yet.
The next several quarters resolve whether new patient starts keep compounding after the first wave of identified adults, whether collections catch the receivable build, and whether a competing DNA medicine with a late-October review date changes the exclusivity narrative. Hub enrollment is already above five hundred patients. The question is whether that funnel still fills after the easiest centers have started therapy.